Australia Cancels More Urogynecological Mesh Licenses
Executive Summary
Registrations for certain transvaginal mesh products are being cancelled by the Australian Therapeutic Goods Administration, and conditions on other mesh and sling products are being imposed.
You may also be interested in...
New Zealand Follows Australia’s Lead In Banning Urogynecological Mesh
Surgical mesh products whose sole use is the treatment of pelvic organ prolapse via transvaginal implantation will no longer be supplied in New Zealand, Medsafe says.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.